Skip to main content

Cephalon

(CEPH)

slipped late Wednesday after guiding toward the low end of Wall Street's 2005 earnings views.

The shortfall came as the West Chester, Pa., drug company posted third-quarter results. Those numbers topped the Wall Street consensus, excluding one-time items from its acquisition of

Cima Labs

and other charges.

Scroll to Continue

TheStreet Recommends

For the three months ended Sept. 30, Cephalon said it recorded adjusted earnings of $46.2 million, or 75 cents a share, on revenue of $262 million. That compares to the average prediction of a profit of $39.8 million, or 67 cents a share, on revenue of $257 million, according to Thomson First Call. These adjusted earnings figures exclude one-time charges.

On a GAAP basis, Cephalon reported a loss of $165.2 million, or $2.94 a share, thanks primarily to charges associated with its acquisition of Cima Labs. Cepahlon recorded a pretax charge of $185.7 million relating to the Cima acquisition. Cephalon also recorded charges totaling $29.6 million due to the exchange of certain notes for common stock and for the repurchase of some notes.

Cephalon said it was refining its 2004 adjusted earnings guidance to $2.35 a share, or 2 cents higher than the Wall Street consensus. Revenue will be in the range of $940 million or $965 million, which is below the Thomson First Call consensus of $987.6 million.

Cephalon also introduced 2005 guidance, predicting an adjusted EPS in the range of $2.80 to $2.95, compared to the Thomson First Call average of $2.94. Cephalon predicted its 2005 sales would be in the range of $1.2 billion to $1.25 billion, compared to the Thomson First Call consensus of $1.22 billion.

The company also pointed out that it had overstated its second-quarter earnings by $1.2 million due to "a clerical error related to the cost of sales in France." As a result, the company decided to restate its second-quarter results.

Cephalon released its financial report after markets had closed. In regular trading, shares rose $1.56, or 3.4%, to $48.07. But in after-hours trading, the stock gave back $1.35, or 2.8%, to $46.72.